Ceritinib provides longer PFS than chemo in phIII trial of ALK rearranged lung cancer
Ceritinib provides longer progression-free survival than chemotherapy in crizotinib-pre-treated patients with non-small-cell lung cancer harbouring an ALK rearrangement, according to results of the phase III ASCEND-5 study ...
Oct 9, 2016
0
0